NPCE icon

Neuropace

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 42.9%
Negative

Neutral
Business Wire
9 days ago
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual Needham Virtual Healthcare Conference at 1:30pm ET (10:30am PT) on Tuesday, April 14, 2026. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for thirty.
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
Positive
Zacks Investment Research
17 days ago
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?
Positive
Zacks Investment Research
17 days ago
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
NPCE rides strong RNS adoption and AI innovation, but near-term profitability faces pressure as IGE expansion and revenue contribution remain uncertain.
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
Positive
Zacks Investment Research
18 days ago
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?
Positive
Zacks Investment Research
1 month ago
NPCE RNS System Explained: Growth Drivers and Setup for 2026
NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.
NPCE RNS System Explained: Growth Drivers and Setup for 2026
Positive
Zacks Investment Research
1 month ago
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026
NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026
Positive
Zacks Investment Research
1 month ago
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand
NPCE's Seizure ID AI tool and potential idiopathic generalized epilepsy approval could expand RNS adoption as NeuroPace pushes software-driven care in 2026.
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand
Neutral
Business Wire
1 month ago
NeuroPace to Present at the Leerink Global Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the Leerink 2026 Global Healthcare Conference at 8:40am PT on Wednesday, March 11, 2026, in Miami, FL. Management will also host investor meetings during the conference. The presentation will be accessible via live webcast here. A webcast replay will be available for thirty days.
NeuroPace to Present at the Leerink Global Healthcare Conference
Positive
The Motley Fool
1 month ago
Why NeuroPace Stock Was Inching Higher on Wednesday
The niche medical devices specialist published its latest quarterly and annual fundamentals. Led by its No.
Why NeuroPace Stock Was Inching Higher on Wednesday
Neutral
Seeking Alpha
1 month ago
NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript
NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript
NeuroPace, Inc. (NPCE) Q4 2025 Earnings Call Transcript